Innate Immunity
Interferon Response
Virus sensing → type I IFN → JAK/STAT → hundreds of ISGs in 4 hours
Type I IFN (α, β) is secreted by virus-infected cells. Binding IFNAR on neighbors activates JAK/STAT, inducing hundreds of antiviral ISGs that block replication — 100-fold rise in 4 hours.
- ISG induction100-fold within 4 hr of IFN exposure
- Type I family13 IFN-α subtypes + IFN-β, ε, κ, ω
- Shared receptorIFNAR1/IFNAR2 heterodimer
- PathwayJAK1/TYK2 → STAT1/STAT2 → ISGF3 → ISRE
- Severe COVID-19~15% explained by anti-IFN autoantibodies
- TherapeuticPEG-IFN-β in MS; IFN-α retired after DAAs for HCV
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
From viral RNA to antiviral state
The interferon response is the cell's emergency broadcast system. One cell discovers it is being hijacked and immediately warns every cell within reach. The mechanism plays out in four phases, each measured in minutes to hours:
- Detection (minutes). Cytoplasmic RIG-I or MDA5 grabs viral RNA carrying the wrong signatures — 5'-triphosphate (RIG-I), long double-stranded (MDA5). cGAS detects cytosolic DNA and makes the cyclic dinucleotide 2'3'-cGAMP, which activates STING on the ER. Endosomal TLR3/7/8/9 see nucleic acid that should not be there.
- Signal convergence (minutes). All sensors lead to TBK1 phosphorylating IRF3 (and IRF7 in a second wave). Phospho-IRF3 dimerizes, enters the nucleus, joins NF-κB and AP-1 on the IFN-β promoter enhanceosome, and transcription begins.
- Secretion and binding (~1 hour). IFN-β is secreted, then auto- and paracrine-binds IFNAR1/IFNAR2 on the same and neighboring cells. JAK1 and TYK2 kinases trans-phosphorylate; STAT1 and STAT2 are recruited and phosphorylated; the ISGF3 trimer (pSTAT1-pSTAT2-IRF9) enters the nucleus.
- ISG induction (1-4 hours). ISGF3 binds ISRE promoter elements. Hundreds of interferon-stimulated genes turn on — many encode direct antiviral effectors: PKR shuts down translation, OAS-RNase L chews viral RNA, Mx GTPases trap nucleocapsids, tetherin holds back budding virions, IFITM blocks fusion, APOBEC3 deaminates viral cDNA, ADAR1 edits viral RNA. MHC class I rises so CD8 T cells can see infected neighbors. ISG transcripts rise 100-fold within 4 hours of IFN exposure.
The result is an antiviral state — neighboring cells are now refractory to viral replication. The virus, which thought it had hours to spread, finds itself walled off within minutes. The interferon response is the reason most viral infections are self-limited.
Worked clinical example: severe COVID-19 in a 58-year-old man
A 58-year-old man arrives at the emergency department with eight days of progressive shortness of breath and a positive SARS-CoV-2 test. He is healthy, runs marathons, no comorbidities. Within 24 hours he is on high-flow oxygen and being considered for intubation. Most peers his age recover; why is he this sick? The 2021 Casanova-Bastard team reported that approximately 15% of severe COVID-19 in previously healthy adults is explained by neutralizing autoantibodies to type I interferons — usually pre-existing for years, often men over 60. A clinical research team sends an anti-IFN autoantibody panel. It returns markedly positive. Plasmapheresis to remove pathogenic autoantibodies, plus baricitinib to suppress secondary cytokine signaling, are added to dexamethasone and remdesivir. He stabilizes by day three and recovers. The mechanism of his severe disease was not an unusual virus; it was a silent gap in his innate antiviral defense — exactly the molecular system this article describes — that the virus exploited.
Why interferons matter clinically
- Innate antiviral defense. The first line against most viral infections — defects unmask severe disease from common pathogens.
- Multiple sclerosis. Pegylated IFN-β reduces relapse rate ~30%; still a first-line option alongside newer agents.
- Hepatitis C history. Pegylated IFN-α plus ribavirin was the standard until 2014; direct-acting antivirals replaced it with higher cure rates and no flu-like toxicity.
- SLE and lupus. Chronic IFN signature drives disease activity; anifrolumab (anti-IFNAR1) is now approved for moderate-to-severe SLE.
- JAK inhibitors. Tofacitinib, baricitinib, ruxolitinib block JAK/STAT signaling for RA, JAK-driven myeloproliferative disease, and severe COVID-19; carry viral reactivation risk.
- Interferonopathies. Aicardi-Goutières, SAVI, STING-associated vasculopathy — monogenic chronic IFN driving autoinflammation; JAK inhibitors stabilize disease.
- Therapeutic IFN-α. Still used in chronic hepatitis B in some settings, hairy cell leukemia, Kaposi sarcoma, and some renal cell carcinomas.
Interferon types compared
| Type I (IFN-α/β) | Type II (IFN-γ) | Type III (IFN-λ) | |
|---|---|---|---|
| Producer cells | Almost any nucleated cell + plasmacytoid DC | Activated T cells, NK cells | Epithelial cells, plasmacytoid DC |
| Receptor | IFNAR1/IFNAR2 (ubiquitous) | IFNGR1/IFNGR2 | IFNLR1/IL-10Rβ (epithelial-restricted) |
| Downstream | JAK1/TYK2 → ISGF3 → ISRE | JAK1/JAK2 → STAT1 homodimer → GAS | JAK1/TYK2 → similar to type I |
| Main role | Antiviral, immunomodulation | Macrophage activation, Th1, anti-TB | Mucosal antiviral defense |
| Side effects | Severe flu-like, depression | Inflammation, autoimmunity | Minimal — restricted distribution |
| Therapeutic use | HCV (historic), HBV, MS, melanoma | Chronic granulomatous disease, NTM | Hepatitis (investigational) |
Common misconceptions
- Interferon means "immune booster." It is an antiviral and immune-modulatory signal, not a general boost; it can suppress as well as activate.
- IFN-γ is the same family as IFN-α. Different receptor, different producers, different effects — just shares the name.
- JAK inhibitors are safe blanket immunomodulators. Block JAK/STAT downstream of IFN; carry herpes zoster, hepatitis B reactivation, and serious infection risk.
- Vaccines induce ISGs equally. Live and mRNA vaccines do (mRNA mildly through TLR/RIG-I), inactivated do not — explains adjuvant biology.
- IFN treats acute COVID-19. Trials of late-phase IFN-α were neutral or harmful; early IFN-λ inhalation showed some benefit but mainstream use remains limited.
- Pathogens cannot evade IFN. Every successful virus encodes IFN antagonists — NS1, nsp1, V protein, NSs, US11 — measure of how strong this defense is.
Frequently asked questions
How does a cell detect that it has been infected?
Cytoplasmic and endosomal sensors of viral nucleic acid. RIG-I detects short 5'-triphosphorylated double-stranded RNA — a signature of replicating RNA viruses (influenza, SARS-CoV-2, HCV). MDA5 detects long dsRNA (picornaviruses). cGAS detects cytoplasmic dsDNA (herpesviruses, HBV, retrovirus reverse transcription intermediates) and synthesizes 2'3'-cGAMP, which activates STING on the ER. Endosomal TLR3, 7, 8, 9 detect ssRNA, dsRNA, and unmethylated CpG DNA. All pathways converge on phosphorylation of IRF3 by TBK1, dimerization, nuclear translocation, and IFN-β transcription — within an hour of detection.
What does IFN do to a cell that receives it?
Receives IFN at IFNAR → JAK1/TYK2 trans-phosphorylation → STAT1 and STAT2 phosphorylation → ISGF3 trimer (pSTAT1-pSTAT2-IRF9) → nuclear translocation → ISRE-driven transcription of hundreds of ISGs. The result is an antiviral state: protein kinase R (PKR) is upregulated and phosphorylates eIF2α to shut down cap-dependent translation, blocking viral protein synthesis. 2'-5' oligoadenylate synthetase (OAS) activates RNase L to chew up viral RNA. Mx GTPases trap nucleocapsids. Tetherin keeps budding virions attached to the membrane. APOBEC3 deaminates viral cDNA. MHC class I expression rises so CD8 T cells can see infected cells. Apoptosis thresholds drop. Within 4 hours, ISG transcripts can rise 100-fold.
How is IFN-α different from IFN-β and IFN-γ?
Type I IFN comprises 13 IFN-α subtypes plus IFN-β, ε, κ, ω — all share the IFNAR1/IFNAR2 receptor. Differences are tissue and cell-of-origin: IFN-β is produced by most nucleated cells on infection; IFN-α is the major product of plasmacytoid dendritic cells (specialized 'IFN-α factories' producing massive amounts). Type II is IFN-γ, produced almost exclusively by activated T cells and NK cells, signaling through a different receptor (IFNGR), driving Th1 responses and macrophage activation — important for intracellular bacteria (TB, listeria) and antitumor immunity. Type III IFN-λ shares ISGs but signals via IFNLR1, restricted to epithelial surfaces — important for mucosal antiviral defense without systemic flu-like side effects.
Why do interferons cause flu-like side effects?
Because high systemic IFN is exactly what your body experiences during a real viral infection — it is the molecular substrate of the 'sick' feeling. IFN crosses the blood-brain barrier and acts on the hypothalamus (fever, anorexia), activates the HPA axis (fatigue), upregulates IL-6 (myalgia), and changes T cell trafficking (lymphopenia). Patients on therapeutic IFN-α for hepatitis C, melanoma, or multiple sclerosis routinely experience fevers, chills, depression (severe enough that depression screening was mandatory), bone marrow suppression, and autoimmune thyroiditis. The discovery that direct-acting antiviral drugs could cure hepatitis C without interferon was one of the most patient-relevant pharmacology advances of the 2010s.
How do viruses evade the interferon response?
Every successful virus encodes evasion. Influenza NS1 inhibits RIG-I activation. SARS-CoV-2 nsp1 shuts down host translation; nsp14 caps viral RNA to mimic host; nsp6 disrupts STING. HCV NS3/4A cleaves MAVS to break the sensing pathway. Vaccinia encodes soluble IFN decoy receptors. EBV and KSHV encode their own IRF homologs that dampen signaling. The intensity of viral counter-measures is a measure of how strong the host IFN defense is — viruses that fail to suppress IFN are usually attenuated and serve as vaccine candidates.
What happens when interferon signaling is broken?
Inborn errors of type I IFN immunity cause severe disease from common viruses. STAT1 loss-of-function gives life-threatening mycobacterial and viral disease. IRF7, IFNAR1, IFNAR2 defects cause severe influenza in children. Most strikingly, two large international studies showed that approximately 15% of life-threatening COVID-19 in previously healthy adults was driven by neutralizing autoantibodies against type I IFN (often pre-existing for years, more common in men and with age). Inhibiting JAK with tofacitinib or baricitinib (autoimmune drugs) carries viral reactivation risk for exactly this reason — herpes zoster, hepatitis B.
What about interferonopathies?
The opposite problem: chronic IFN overactivation. Mutations in TREX1, RNase H2, SAMHD1, ADAR1, IFIH1 (gain-of-function MDA5), STING (SAVI syndrome), or PSMB8 cause monogenic interferonopathies — chronic ISG signature, skin and brain inflammation, calcifications. Aicardi-Goutières syndrome is the prototype: TREX1 deficiency allows endogenous retroelement cDNAs to accumulate and drive constitutive cGAS-STING activity. JAK inhibitors (baricitinib, ruxolitinib) can suppress the IFN signature and stabilize disease. Polygenic interferonopathy — chronic high IFN signature — is also seen in systemic lupus erythematosus and is targeted by anifrolumab (anti-IFNAR1).